Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

MLA

George S. Vassiliou, et al. “Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib.” Nature Medicine, vol. 24, July 2018, pp. 1167–77. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7d30ad4500bdf6ee72adaf9de1577627&authtype=sso&custid=ns315887.

APA

George S. Vassiliou, Eytan M. Stein, Cyril Quivoron, Ross L. Levine, Lynn Quek, Stéphane de Botton, Paresh Vyas, Bilyana Stoilova, Michael Amatangelo, Alison Kennedy, M. S. Vijayabaskar, Alan Shih, O. Bernard, Virginie Penard-Lacronique, Katharine E. Yen, Véronique Saada, Maël Heiblig, Samar Alsafadi, Marlen Metzner, … Christophe Willekens. (2018). Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 24, 1167–1177.

Chicago

George S. Vassiliou, Eytan M. Stein, Cyril Quivoron, Ross L. Levine, Lynn Quek, Stéphane de Botton, Paresh Vyas, et al. 2018. “Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib.” Nature Medicine 24 (July): 1167–77. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7d30ad4500bdf6ee72adaf9de1577627&authtype=sso&custid=ns315887.